Although integrase inhibitors such as dolutegravir are recommended for the treatment of HIV-2, there is little clinical data showing their effectiveness. In a small Portuguese cohort, dolutegravir combined with two other drugs suppressed HIV-2 viral load and maintained undetectable status after one year. In their paper published in the journal of Clinical Infectious Diseases, the authors conclude dolutegravir-based triple therapy is a safe and effective initial therapy option for the treatment of HIV-2.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Switching ART regimens common in virologically suppressed HIV
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.